ArticleBlood2017

Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.

Alan S Wayne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.